|
1
|
von Hoff K, Hinkes B, Gerber NU, Deinlein
F, Mittler U, Urban C, Benesch M, Warmuth-Metz M, Soerensen N,
Zwiener I, Goette H, Schlegel PG, Pietsch T, Kortmann RD, Kuehl J
and Rutkowski S: Long-term outcome and clinical prognostic factors
in children with medulloblastoma treated in the prospective
randomised multicentre trial HIT’91. Eur J Cancer. 45:1209–1217.
2009.PubMed/NCBI
|
|
2
|
Massimino M, Giangaspero F, Garrè ML,
Gandola L, Poggi G, Biassoni V, Gatta G and Rutkowski S: Childhood
medulloblastoma. Crit Rev Oncol Hematol. 79:65–83. 2011. View Article : Google Scholar
|
|
3
|
Gilbertson RJ: Medulloblastoma: signalling
a change in treatment. Lancet Oncol. 5:209–218. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Leary SE and Olson JM: The molecular
classification of medulloblastoma: driving the next generation
clinical trials. Curr Opin Pediatr. 24:33–39. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wierstra I and Alves J: FOXM1, a typical
proliferation-associated transcription factor. Biol Chem.
388:1257–1274. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Laoukili J, Kooistra MR, Brás A, Kauw J,
Kerkhoven RM, Morrison A, Clevers H and Medema RH: FoxM1 is
required for execution of the mitotic programme and chromosome
stability. Nat Cell Biol. 7:126–136. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Koo CY, Muir KW and Lam EW: FOXM1: from
cancer initiation to progression and treatment. Biochim Biophys
Acta. 1819:28–37. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu M, Dai B, Kang SH, Ban K, Huang FJ,
Lang FF, Aldape KD, Xie TX, Pelloski CE, Xie K, Sawaya R and Huang
S: FoxM1B is overexpressed in human glioblastomas and critically
regulates the tumorigenicity of glioma cells. Cancer Res.
66:3593–3602. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bektas N, Haaf At, Veeck J, Wild PJ,
Lüscher-Firzlaff J, Hartmann A, Knüchel R and Dahl E: Tight
correlation between expression of the Forkhead transcription factor
FOXM1 and HER2 in human breast cancer. BMC Cancer. 8:422008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ahmed M, Uddin S, Hussain AR, Alyan A,
Jehan Z, Al-Dayel F, Al-Nuaim A, Al-Sobhi S, Amin T, Bavi P and
Al-Kuraya KS: FoxM1 and its association with matrix
metalloproteinase (MMP) signaling pathway in papillary thyroid
carcinoma. J Clin Endocrinol Metab. 97:E1–E13. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xia JT, Wang H, Liang LJ, Peng BG, Wu ZF,
Chen LZ, Xue L, Li Z and Li W: Overexpression of FOXM1 is
associated with poor prognosis and clinicopathologic stage of
pancreatic ductal adenocarcinoma. Pancreas. 41:629–635. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Priller M, Pöschl J, Abrão L, von Bueren
AO, Cho YJ, Rutkowski S, Kretzschmar HA and Schüller U: Expression
of FoxM1 is required for the proliferation of medulloblastoma cells
and indicates worse survival of patients. Clin Cancer Res.
17:6791–6801. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Carr JR, Park HJ, Wang Z, Kiefer MM and
Raychaudhuri P: FoxM1 mediates resistance to herceptin and
paclitaxel. Cancer Res. 70:5054–5063. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Millour J, Constantinidou D, Stavropoulou
AV, Wilson MS, Myatt SS, Kwok JM, Sivanandan K, Coombes RC, Medema
RH, Hartman J, Lykkesfeldt AE and Lam EW: FOXM1 is a
transcriptional target of ERalpha and has a critical role in breast
cancer endocrine sensitivity and resistance. Oncogene.
29:2983–2995. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kwok JM, Peck B, Monteiro LJ, Schwenen HD,
Millour J, Coombes RC, Myatt SS and Lam EW: FOXM1 confers acquired
cisplatin resistance in breast cancer cells. Mol Cancer Res.
8:24–34. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Halasi M and Gartel AL: Suppression of
FOXM1 sensitizes human cancer cells to cell death induced by
DNA-damage. PLoS One. 7:e317612010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kwok JM, Myatt SS, Marson CM, Coombes RC,
Constantinidou D and Lam EW: Thiostrepton selectively targets
breast cancer cells through inhibition of forkhead box M1
expression. Mol Cancer Ther. 7:2022–2032. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hegde NS, Sanders DA, Rodriguez R and
Balasubramanian S: The transcription factor FOXM1 is a cellular
target of the natural product thiostrepton. Nat Chem. 3:725–731.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bhat UG, Halasi M and Gartel AL: FoxM1 is
a general target for proteasome inhibitors. PLoS One. 4:e65932009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bhat UG, Halasi M and Gartel AL: Thiazole
antibiotics target FoxM1 and induce apoptosis in human cancer
cells. PLoS One. 4:e55922009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Halasi M, Schraufnagel DP and Gartel AL:
Wild-type p53 protects normal cells against apoptosis induced by
thiostrepton. Cell Cycle. 8:2850–2851. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Halasi M, Zhao H, Dahari H, Bhat UG,
Gonzalez EB, Lyubimo AV, Tonetti DA and Gartel AL: Thiazole
antibiotics against breast cancer. Cell Cycle. 9:1214–1217. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang M and Gartel AL: Micelle-encapsulated
thiostrepton as an effective nanomedicine for inhibiting tumor
growth and for suppressing FOXM1 in human xenografts. Mol Cancer
Ther. 10:2287–2297. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang Y, Wen L, Zhao SH, Ai ZH, Guo JZ and
Liu WC: FoxM1 expression is significantly associated with
cisplatin-based chemotherapy resistance and poor prognosis in
advanced non-small cell lung cancer patients. Lung Cancer.
79:173–179. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang N, Wu X, Yang L, Xiao F, Zhang H,
Zhou A, Huang Z and Huang S: FoxM1 inhibition sensitizes resistant
glioblastoma cells to temozolomide by downregulating the expression
of DNA-repair gene Rad51. Clin Cancer Res. 18:5961–5971.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xu N, Zhang X, Wang X, Ge HY, Wang XY,
Garfield D, Yang P, Song YL and Bai CX: FoxM1 mediated resistance
to gefitinib in non-small-cell lung cancer cells. Acta Pharmacol
Sin. 33:675–681. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Park HJ, Gusarova G, Wang Z, Carr JR, Li
J, Kim KH, Qiu J, Park YD, Williamson PR, Hay N, Tyner AL, Lau LF,
Costa RH and Raychaudhuri P: Deregulation of FoxM1b leads to tumour
metastasis. EMBO Mol Med. 3:21–34. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lok GT, Chan DW, Liu VW, Hui WW, Leung TH,
Yao KM and Ngan HY: Aberrant activation of ERK/FOXM1 signaling
cascade triggers the cell migration/invasion in ovarian cancer
cells. PLoS One. 6:e237902011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Huang C, Qiu Z, Wang L, Peng Z, Jia Z,
Logsdon CD, Le X, Wei D, Huang S and Xie K: A novel FoxM1-caveolin
signaling pathway promotes pancreatic cancer invasion and
metastasis. Cancer Res. 72:655–665. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kim R, Emi M, Tanabe K and Toge T:
Therapeutic potential of antisense Bcl-2 as a chemosensitizer for
cancer therapy. Cancer. 101:2491–2502. 2004. View Article : Google Scholar : PubMed/NCBI
|
